Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by independent educational grants from AbbVie, Inc.; Pfizer, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Target Audience: The intended audience for the activities is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).
Learning Objectives: Upon successful completion of this educational series, participants should be better able to:
- Determine the role of laboratory, endoscopic, and imaging studies in the diagnosis and classification patients with suspected IBD.
- Analyze the potential role of emerging therapies with novel mechanisms of action in patients with IBD refractory to current therapeutic options.
- Apply therapeutic drug monitoring as needed to optimize the management of IBD.
Steering Committee & Faculty:
Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
William J. Sandborn, MD
Professor of Medicine
Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Vice Chair for Clinical Operations, Department of Medicine
Director, UCSD IBD Center
University of California, San Diego & UC San Diego Health System
La Jolla, CA
Reviewer:
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, November 27, 2017 through November 26, 2018.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Steering Committee & Faculty members report the following relationship(s):
Stephen B. Hanauer, MD
Consulting Fee: AbbVie, Boehringer-Ingelheim, Celgene, Celltrion, Hospira, Janssen, Lilly, Merck, Pfizer, Prometheus, Receptos, Salix, Samsung Bioepis, Shire, Takeda, UCB Pharma
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research (paid to institution): AbbVie, Celgene, Janssen, Lilly, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Gary R. Lichtenstein, MD
Royalty: SLACK, Inc.
Consulting Fee: Abbott/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer, Prometheus, Romark, Salix, Santarus, Shire, Takeda, UCB
Contracted Research (paid to institution): Ferring, Prometheus, Salix, Santarus, Shire, UCB
Research Grant: Janssen Orthobiotech
Author Honoraria: McMahon Publishing, Up-to-Date
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media
William J. Sandborn, MD
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen Idec, Boehringer-Ingelheim, Celgene, Galapagos, Genentech, Gilead Sciences, Janssen, Lilly, MedImmune, Oppilan, Pfizer, Receptos, Shire, Takeda, Therakos
Speakers Bureau: AbbVie, Janssen, Takeda
Non-CME Services: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen Idec, Boehringer-Ingelheim, Celgene, Galapagos, Genentech, Gilead Sciences, Janssen, Lilly, MedImmune, Oppilan, Pfizer, Receptos, Shire, Takeda, Therakos
Contracted Research: AbbVie, Amgen, Genentech, Gilead Sciences, Janssen, Pfizer, Receptos, Takeda
Ownership Interest: Oppilan
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com